uniQure N.V. Faces Class Action Lawsuits Over Alleged Securities Violations and Misleading Statements

uniQure N.V. Faces Class Action Lawsuits Over Alleged Misstatements

In a significant development for uniQure N.V., two law firms have initiated class action lawsuits against the company for alleged violations of the Securities Exchange Act of 1934. The lawsuits target investors who purchased uniQure's securities between September 24, 2025, and October 31, 2025. Allegations include misleading statements made by the company concerning its progress towards obtaining FDA approval for its pivotal study related to its Biologics License Application (BLA). The complainants claim that uniQure downplayed potential delays, leading investors to believe the approval process was more straightforward than it actually was.

The lawsuits assert that uniQure's public statements during the class period contained significant inaccuracies regarding the Pivotal Study's timeline and the requirements for FDA approval. Investors contend that these misrepresentations have resulted in considerable financial losses when the truth about the company's standing was ultimately revealed. With the class action still pending certification, potential participants are encouraged to act quickly, as the deadline to join the lawsuits is April 13, 2026. Interested investors can contact the law firms for more details on how to proceed.

While uniQure has not publicly responded to the lawsuits, the company may need to navigate a challenging legal landscape if the allegations hold merit. The outcome of these cases could have long-lasting implications not just for the company but also for its ongoing efforts in the competitive landscape of gene therapy and rare disease treatment. Stakeholders will be closely monitoring any developments as uniQure attempts to clarify its position regarding the allegations, particularly concerning its regulatory submissions and communication practices.

In addition to the legal proceedings, investment advocacy groups are closely watching the situation, emphasizing the importance of transparency in the biotech industry. Firms like The Schall Law Firm and DJS Law Group have made it clear that affected shareholders should take action to protect their interests, emphasizing that involvement in the lawsuits does not require being appointed as a lead plaintiff.

As these legal proceedings unfold, uniQure faces the dual challenge of maintaining investor confidence while addressing the ramifications of the allegations. The company’s response to the class-action lawsuits will be pivotal in shaping its reputation and possibly influencing its future operations within the highly regulated pharmaceutical sector.